The search for new DHFR inhibitors: a review of patents, January 2001 – February 2005
暂无分享,去创建一个
Teodorico C. Ramalho | E. F. D. da Cunha | E. Maia | R. B. de Alencastro | Teodorico C Ramalho | Elaine Fontes F da Cunha | Elaine R Maia | Ricardo Bicca de Alencastro | E. D. da Cunha
[1] A. Rosowsky,et al. Further studies on the interaction of nonpolyglutamatable aminopterin analogs with dihydrofolate reductase and the reduced folate carrier as determinants of in vitro antitumor activity. , 2003, Biochemical pharmacology.
[2] R. Durand,et al. Dihydrofolate reductase inhibitors: new developments in antiparasitic chemotherapy , 2001 .
[3] A. Rosowsky,et al. Efficient utilization of the reduced folate carrier in CCRF-CEM human leukemic lymphoblasts by the potent antifolate N(alpha)-(4-amino-4-deoxypteroyl)-N(delta)-hemiphthaloyl-L- ornithine (PT523) and its B-ring analogues. , 2000, Biochemical pharmacology.
[4] Amy C Anderson,et al. Targeting DHFR in parasitic protozoa. , 2005, Drug discovery today.
[5] T. Reese,et al. In vivo magnetic resonance methods in pharmaceutical research: current status and perspectives , 1999, NMR in biomedicine.
[6] J. Åqvist,et al. Design, synthesis, and computational affinity prediction of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. , 2004, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[7] R. Haynes,et al. dUTP pyrophosphatase as a potential target for chemotherapeutic drug development. , 1997, Acta biochimica Polonica.
[8] S. Queener,et al. Inhibition of Pneumocystis carinii, Toxoplasma gondii, and Mycobacterium avium dihydrofolate reductases by 2,4-diamino-5-[2-methoxy-5-(omega-carboxyalkyloxy)benzyl]pyrimidines: marked improvement in potency relative to trimethoprim and species selectivity relative to piritrexim. , 2002, Journal of medicinal chemistry.
[9] S. P. Greatbanks,et al. Computational Methods for the Study of Enzymic Reaction Mechanisms. 1. Application to the Hydride Transfer Step in the Catalysis of Dihydrofolate Reductase , 2002 .
[10] G. Curt,et al. Formation of methotrexate polyglutamates in purified myeloid precursor cells from normal human bone marrow. , 1985, The Journal of clinical investigation.
[11] N Bodor,et al. Soft drug design: General principles and recent applications , 2000, Medicinal research reviews.
[12] H Schenone,et al. [Special program for research and training in tropical diseases]. , 1998, Annales de la Societe belge de medecine tropicale.
[13] Maria Paola Costi,et al. Update on antifolate drugs targets. , 2001, Current drug targets.
[14] C. Inderlied,et al. New 2,4-diamino-5-(2',5'-substituted benzyl)pyrimidines as potential drugs against opportunistic infections of AIDS and other immune disorders. Synthesis and species-dependent antifolate activity. , 2004, Journal of medicinal chemistry.
[15] Interactions of 5-deazapteridine Derivatives with Mycobacterium tuberculosis and with Human Dihydrofolate Reductases , 2004, Journal of biomolecular structure & dynamics.
[16] Robert C. Reynolds,et al. Antimycobacterial Activities of 2,4-Diamino-5-Deazapteridine Derivatives and Effects on Mycobacterial Dihydrofolate Reductase , 2000, Antimicrobial Agents and Chemotherapy.
[17] A. Smith,et al. Genetic characterization of trimethoprim resistance in Haemophilus influenzae , 1996, Antimicrobial agents and chemotherapy.
[18] A. Rosowsky,et al. Synthesis and Potent Antifolate Activity and Cytotoxicity of B-Ring Deaza Analogues of the Nonpolyglutamatable Dihydrofolate Reductase Inhibitor Nα-(4-Amino-4-deoxypteroyl)-Nδ-hemiphthaloyl-l-ornithine (PT523) , 1998 .
[19] S F Queener,et al. Design, synthesis, computational prediction, and biological evaluation of ester soft drugs as inhibitors of dihydrofolate reductase from Pneumocystis carinii. , 2001, Journal of medicinal chemistry.
[20] D. W. Fry,et al. Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. , 1983, Cancer research.
[21] P. Olliaro,et al. Mode of action and mechanisms of resistance for antimalarial drugs. , 2001, Pharmacology & therapeutics.
[22] James Inglese,et al. gamma-Fluoromethotrexate: synthesis and biological activity of a potent inhibitor of dihydrofolate reductase with greatly diminished ability to form poly-gamma-glutamates. , 1985, Proceedings of the National Academy of Sciences of the United States of America.
[23] Debabrata Banerjee,et al. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. , 2002, Biochimica et biophysica acta.
[24] D E Snider,et al. Global epidemiology of tuberculosis. Morbidity and mortality of a worldwide epidemic. , 1995, JAMA.
[25] F. M. Huennekens. In search of dihydrofolate reductase , 1996, Protein science : a publication of the Protein Society.
[26] A. Rosowsky,et al. Synthesis of the Folylpolyglutamate Synthetase Inhibitor Nα-Pteroyl-Lornithine and its Nδ-Benzoyl and Nδ-Hemiphthaloyl Derivatives, and an Improved Synthesis of Nα-( 4-Amino-4-deoxypteroy1)-Nδ-hemiphthaloyl-Lornithine , 1989 .
[27] D. Crowther,et al. Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] C. Presant,et al. Non‐invasive 19F‐NMRS of 5‐fluorouracil in pharmacokinetics and pharmacodynamic studies , 1998, NMR in biomedicine.
[29] J. A. Donkersloot,et al. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in Streptococcus pneumoniae. , 1998, The Journal of infectious diseases.
[30] R. Rappuoli,et al. The impact of genomics on vaccine design. , 2005, Trends in biotechnology.
[31] O. Santos-Filho,et al. Type 2 antifolates in the chemotherapy of falciparum malaria , 2002 .
[32] L F Kuyper,et al. X-Ray crystal structures of Candida albicans dihydrofolate reductase: high resolution ternary complexes in which the dihydronicotinamide moiety of NADPH is displaced by an inhibitor. , 2001, Journal of medicinal chemistry.
[33] A. Rosowsky,et al. Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. , 1995, Molecular pharmacology.
[34] J. Bertino,et al. Karnofsky memorial lecture. Ode to methotrexate. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[35] J. Gready,et al. Energetically most likely substrate and active-site protonation sites and pathways in the catalytic mechanism of dihydrofolate reductase. , 2001, Journal of the American Chemical Society.
[36] A. Rosowsky,et al. Biochemical studies on PT523, a potent nonpolyglutamatable antifolate, in cultured cells. , 1994, Molecular pharmacology.
[37] K Bowden,et al. Structure-activity relationships of dihydrofolate reductase inhibitors. , 1993, Journal of chemotherapy.
[38] G. Eliopoulos,et al. Resistance to trimethoprim-sulfamethoxazole. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[39] J. Koutcher,et al. A fluorine-labeled methotrexate as a probe for monitoring tumor antifolate pharmacokinetics: synthesis, in vitro cytotoxicity, and pilot in vivo 19F magnetic resonance spectra. , 2003, Molecular cancer therapeutics.
[40] A. Rosowsky. PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. , 1999, Current medicinal chemistry.
[41] Jeffrey M. Blaney,et al. Structure-activity relationships of dihydrofolated reductase inhibitors , 1984 .
[42] Yongyuth Yuthavong,et al. Insights into antifolate resistance from malarial DHFR-TS structures , 2003, Nature Structural Biology.
[43] R. Moran,et al. Methotrexate analogues. 33. N delta-acyl-N alpha-(4-amino-4-deoxypteroyl)-L-ornithine derivatives: synthesis and in vitro antitumor activity. , 1988, Journal of medicinal chemistry.
[44] Gerd Folkers,et al. Molecular Modeling, Basic Principles and Applications , 1996 .
[45] R. Reynolds,et al. Susceptibilities of Mycobacterium tuberculosis and Mycobacterium avium complex to lipophilic deazapteridine derivatives, inhibitors of dihydrofolate reductase. , 1998, The Journal of antimicrobial chemotherapy.
[46] L. Amzel,et al. Tuberculosis drug targets. , 2002, Current drug targets.
[47] R. M. Hyde,et al. 2,4-Diamino-5-benzylpyrimidines as antibacterial agents. 7. Analysis of the effect of 3,5-dialkyl substituent size and shape on binding to four different dihydrofolate reductase enzymes. , 1987, Journal of medicinal chemistry.
[48] K. Keyomarsi,et al. Synthesis and Biological Activity of Nω-Hemiphthaloyl-α,ω-diaminoalkanoic Acid Analogues of Aminopterin and 3′,5-Dichloroaminopterin , 1994 .
[49] K. Rieckmann,et al. Phenoxypropoxybiguanides, prodrugs of DHFR-inhibiting diaminotriazine antimalarials. , 2001, Journal of medicinal chemistry.
[50] E. Brown,et al. High throughput screening identifies novel inhibitors of Escherichia coli dihydrofolate reductase that are competitive with dihydrofolate. , 2003, Bioorganic & medicinal chemistry letters.
[51] W G Hol,et al. Three-dimensional structure of M. tuberculosis dihydrofolate reductase reveals opportunities for the design of novel tuberculosis drugs. , 2000, Journal of molecular biology.
[52] S. Bushby,et al. Trimethoprim, a sulphonamide potentiator. , 1968, British journal of pharmacology and chemotherapy.
[53] M. Page,et al. A single amino acid substitution in Staphylococcus aureus dihydrofolate reductase determines trimethoprim resistance. , 1997, Journal of molecular biology.
[54] L. Kuyper,et al. Selective inhibitors of Candida albicans dihydrofolate reductase: activity and selectivity of 5-(arylthio)-2,4-diaminoquinazolines. , 1995, Journal of medicinal chemistry.
[55] R. Then,et al. DNA and RNA synthesis: antifolates. , 2005, Chemical reviews.
[56] J. Maddry,et al. Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. , 2001, The Journal of antimicrobial chemotherapy.